Department of Environmental and Molecular Health Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University 5-1 Oe-honmachi, Kumamoto 862-0973, Japan.
Behav Brain Res. 2012 Jan 15;226(2):381-5. doi: 10.1016/j.bbr.2011.09.031. Epub 2011 Oct 5.
We previously reported that the centrally acting non-narcotic antitussive, tipepidine, produces a novel antidepressant-like effect in the forced swimming test in rats, but the mechanism of the antidepressant-like effect of tipepidine is not clear. We investigated the pharmacological mechanism of the antidepressant-like effect of tipepidine in the forced swimming test in rats. A catecholamine-depleting agent, alpha-methyl-p-tyrosine (AMPT; 300 mg/kg, s.c.), was given 6h before the first injection and with the last injection of tipepidine (40 mg/kg, i.p.). A serotonin (5-HT)-depleting agent, p-chlorophenylalanine (PCPA; 350 mg/kg, i.p.), was given 72 h and 48 h before the pretest session. The dopamine D(1) receptor antagonist, SCH23390 (0.02 mg/kg, s.c.) was given 15min before each of the three injections of tipepidine. The dopamine D(2) receptor antagonist raclopride (0.2mg/kg, s.c.), the alpha 1 adrenoceptor antagonist prazosin (1mg/kg, i.p.), the alpha 2 adrenoceptor antagonist yohimbine (2mg/kg, i.p.) and the beta adrenoceptor antagonist propranolol (2mg/kg, i.p.) were given 30 min before each of the three injections of tipepidine. AMPT, but not PCPA, significantly inhibited the immobility time-reducing effect of tipepidine in the forced swimming test. Furthermore, the effect of tipepidine was significantly inhibited by SCH23390 and yohimbine. However, raclopride, prazosin, and propranolol failed to block the effect of tipepidine. The results suggest that the antidepressant-like effect of tipepidine in the forced swimming test may be due at least in part to the effects of dopamine and noradrenaline released at the dopamine D(1) receptor and alpha 2 adrenoceptor, respectively.
我们之前报道过中枢作用的非麻醉性镇咳药替派啶在大鼠强迫游泳试验中产生一种新型的抗抑郁样作用,但替派啶抗抑郁样作用的机制尚不清楚。我们研究了替派啶在大鼠强迫游泳试验中的抗抑郁样作用的药理学机制。在第一次注射前 6 小时和替派啶(40mg/kg,ip)的最后一次注射时给予儿茶酚胺耗竭剂α-甲基-对酪氨酸(AMPT;300mg/kg,sc)。在预测试前 72 小时和 48 小时给予 5-羟色胺(5-HT)耗竭剂对氯苯丙氨酸(PCPA;350mg/kg,ip)。多巴胺 D1 受体拮抗剂SCH23390(0.02mg/kg,sc)在替派啶的三次注射前 15 分钟给予。多巴胺 D2 受体拮抗剂氯丙嗪(0.2mg/kg,sc)、α1 肾上腺素受体拮抗剂哌唑嗪(1mg/kg,ip)、α2 肾上腺素受体拮抗剂育亨宾(2mg/kg,ip)和β肾上腺素受体拮抗剂普萘洛尔(2mg/kg,ip)在替派啶的三次注射前 30 分钟给予。AMPT,但不是 PCPA,显著抑制了替派啶在强迫游泳试验中减少不动时间的作用。此外,替派啶的作用明显被 SCH23390 和育亨宾抑制。然而,氯丙嗪、哌唑嗪和普萘洛尔未能阻断替派啶的作用。结果表明,替派啶在强迫游泳试验中的抗抑郁样作用至少部分是由于多巴胺和去甲肾上腺素分别在多巴胺 D1 受体和α2 肾上腺素受体上释放所致。